Lv3
270 积分 2022-08-15 加入
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2小时前
待确认
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer
1个月前
已完结
Response assessment criteria for brain metastases: proposal from the RANO group
5个月前
已完结
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis
5个月前
已完结
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
6个月前
已完结
[Interpretation of the 5th WHO classification of thoracic tumors: tumors of the pleura and pericardium]
6个月前
已完结
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations
6个月前
已完结
Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
8个月前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
8个月前
已完结
Cancer incidence and mortality in China, 2022
8个月前
已完结
皖公网安备34019202002308
